Flatiron Health's Bobby Green Outlines Cancer Clinical Trial to Understand Genomic Changes in Tumors (Pt. 5)

Article

During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech presented plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials. The idea is to collect blood samples using Foundation Medicine’s liquid biopsy assay and analyze the results through Flatiron’s platform, to see if genomic changes can be detected over the course of cancer treatment. Bobby Green, MD, chief medical officer for Flatiron Health, spoke with Managed Healthcare Executive®.

Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 Kol is featured in this series
1 Kol is featured in this series
Why consumer price transparency for medication is so important
Related Content
© 2024 MJH Life Sciences

All rights reserved.